• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Iris Acquisition Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    9/10/24 4:01:37 PM ET
    $IRAA
    Blank Checks
    Finance
    Get the next $IRAA alert in real time by email
    false --12-31 0001831874 0001831874 2024-09-04 2024-09-04 0001831874 IRAAU:UnitMember 2024-09-04 2024-09-04 0001831874 us-gaap:CommonClassAMember 2024-09-04 2024-09-04 0001831874 us-gaap:WarrantMember 2024-09-04 2024-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported):  September 4, 2024

     

    IRIS ACQUISITION CORP

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40167   85-3901431
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    3rd Floor Zephyr House

    122 Mary Street, George Town

    PO Box 10085

    Grand Cayman KY1-1001, Cayman Islands

    (Address of principal executive offices) (Zip Code)  

     

    Registrant’s telephone number, including area code: 971 4 3966949

     

    (Former name or former address, if changed since last report)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each
    exchange on
    which registered
             
    Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant   IRAAU   The Nasdaq Stock Market LLC
             
    Class A Common Stock, par value $0.0001 per share   IRAA   The Nasdaq Stock Market LLC
             
    Warrants, each exercisable for one share of Class A Common Stock $11.50 per share   IRAAW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

      

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously reported, Iris Acquisition Corp (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to comply with Nasdaq Listing Rule IM-5101-2 (“Rule IM-5101-2”), which requires that a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement (the “Nasdaq Deadline”). The Company submitted a request for a hearing with Nasdaq to appeal the delisting determination on March 12, 2024. On May 2, 2024, the Company received a written notice from the Listing Qualifications Department of Nasdaq, notifying the Company that because it no longer met the minimum 500,000 publicly held shares requirement for The Nasdaq Capital Market under Nasdaq Listing Rule 5810(d)(2), this deficiency was an additional basis for delisting and the Company would also need to address this deficiency at the Hearing. On May 9, 2024, the Nasdaq Hearings Panel (the “Panel”) convened to hear the Company’s appeal. On May 21, 2024, the Company received a response from the Panel granting the Company’s request for continued listing on The Nasdaq Capital Market. The Company had until September 3, 2024, to demonstrate compliance with all applicable requirements for initial listing on The Nasdaq Global Market by the Company’s successor, Iris Parent Holding Corp.

     

    On September 4, 2024, the Company received a notice (the “Delisting Notice”) from Nasdaq stating that Nasdaq has determined to delist the Company’s securities on The Nasdaq Capital Market. Trading was suspended in the Company’s securities effective at the open of business on September 6, 2024.

     

    Following the suspension of trading on The Nasdaq Capital Market, the Company’s Units, shares of Class A common stock and warrants will be eligible to trade on the OTC Pink Marketplace under the symbols “IRAAU,” “IRAA” and “IRAAW,” respectively. Nasdaq will complete the delisting by filing a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities and Exchange Act of 1934, as amended, on Form 25 with the U.S. Securities and Exchange Commission.

     

    Notwithstanding the delisting of the Company’s securities from Nasdaq, it remains the intention of the Company to continue to pursue the previously disclosed proposed business combination, as well as the listing of securities of Iris Parent Holding Corp. on Nasdaq.

     

    Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On September 5, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to the Company’s amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to December 31, 2024 (the “Extension Amendment”).

     

    The Company’s stockholders approved the Extension Amendment at a special meeting of stockholders of the Company (the “Special Meeting”) on September 5, 2024. The foregoing description of the Extension Amendment is qualified in its entirety by the full text of the Extension Amendment, which is filed as Exhibit 3.1 hereto and incorporated herein by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On September 5, 2024, at the Special Meeting, a total of 7,043,238 (or 98%) of the Company’s issued and outstanding shares of Class A common stock held of record as of August 19, 2024, the record date for the Special Meeting, were present either in person or by proxy, which constituted a quorum. The Company’s stockholders voted on the following proposals at the Special Meeting, each of which were approved. The final vote tabulation for each proposal is set forth below.

     

    Proposal 1. To approve amendments to the Company’s charter to change the date by which the Company must consummate a business combination to December 31, 2024 (subject to an additional three month extension at the discretion of the Board) (the “Extension Proposal”.)

     

    For   Against   Abstained   Broker Non-Votes
    7,043,238   0   0   0

     

     

     

     

    Proposal 2. To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Proposal.

     

    For   Against   Abstained   Broker Non-Votes
    7,043,238   0   0   0

     

    Although this proposal would have received sufficient votes to be approved, no motion to adjourn was made because the adjournment of the Special Meeting was determined not to be necessary or appropriate.

     

    In connection with the Special Meeting, stockholders holding 48,107 shares properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $11.02 per share, subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax. Following such redemptions, approximately $2,655,144.77 will be left in trust, subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax and 7,138,930 shares will remain outstanding.

     

     

     

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
    3.1   Amendment to the Amended and Restated Certificate of Incorporation of Iris Acquisition Corp, filed on September 5, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        IRIS ACQUISITION CORP
         
    Date: September 10, 2024 By: /s/ Sumit Mehta
        Name: Sumit Mehta
        Title: Chief Executive Officer

     

     

     

    Get the next $IRAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRAA
    SEC Filings

    View All

    SEC Form 15-12G filed by Iris Acquisition Corp

    15-12G - Iris Acquisition Corp (0001831874) (Filer)

    4/30/25 9:25:13 AM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 10-K filed by Iris Acquisition Corp

    10-K - Iris Acquisition Corp (0001831874) (Filer)

    4/15/25 9:48:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form NT 10-K filed by Iris Acquisition Corp

    NT 10-K - Iris Acquisition Corp (0001831874) (Filer)

    3/31/25 4:01:42 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Legion Partners Issues Letter to The Chefs' Warehouse, Inc. Shareholders Calling for Urgently Needed Board Change

    Highlights Company's Chronic Operational and Share Price Underperformance and the Need for New Skill Sets in the Boardroom to Help Chef Reach its Full Potential Nominates Four Highly Qualified, Independent Directors Who Would Bring Valuable Experience in Operations, Finance, Information Systems, Capital Allocation and Strategic Planning to the Board Legion Partners Asset Management, LLC, together with its affiliates (collectively, "we" or "Legion Partners"), is a significant shareholder of The Chefs' Warehouse, Inc. ("Chef", or the "Company") (NASDAQ:CHEF). Today, Legion Partners issued a public letter to the Company's shareholders announcing its nomination of four candidates to the Boa

    2/8/24 8:30:00 AM ET
    $AMPS
    $CHEF
    $F
    Electric Utilities: Central
    Utilities
    Food Distributors
    Consumer Discretionary

    Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

    NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (NASDAQ:IRAA), a publicly traded special purpose acquisition company ("SPAC") formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15

    12/5/22 7:00:00 AM ET
    $IRAA
    Blank Checks
    Finance

    Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments

    Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma The transaction values the combined companies at a pro forma enterprise value of $334 million The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor. The GCC vaccine and CAR-T patent portfolio originated from Thomas Jefferson University (TJU). The CD47 checkpoint inhibitor originates from a South Korean biotech company InnoBation Bio Co. Ltd. The transaction is expected to be completed in the first half of 2023 Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company develo

    11/30/22 8:46:00 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Saba Capital Management, L.P. sold $8,781,435 worth of shares (853,395 units at $10.29) (SEC Form 4)

    4 - Iris Acquisition Corp (0001831874) (Issuer)

    9/28/23 10:05:40 AM ET
    $IRAA
    Blank Checks
    Finance

    New insider Moore Capital Management, Lp claimed ownership of 100,000 shares (SEC Form 3)

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    9/26/23 4:43:11 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 3: New insider Saba Capital Management, L.P. claimed ownership of 853,395 shares

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    2/23/23 1:13:50 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/14/24 5:28:26 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/13/24 5:52:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    9/27/23 11:10:24 AM ET
    $IRAA
    Blank Checks
    Finance